CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in CNS Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −4 vs. Q4 2021
- Shares held
- 1.73M
- +558.5K (+47.5%) vs. Q4 2021
- Total value
- $589.0K
- −$239.0K (−28.9%) vs. Q4 2021
- New holders
- 4
- 6 more added
- Sold out
- 8
- 4 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 506,532 | $173.0K | 0.00% | +358,832+242.9% | Added |
| Vanguard Group Inc | 427,703 | $146.0K | 0.00% | −181,706−29.8% | Reduced |
| Bank of New York Mellon Corp | 234,892 | $80.0K | 0.00% | +205,134+689.3% | Added |
| Geode Capital Management, LLC | 129,016 | $43.0K | 0.00% | +21,754+20.3% | Added |
| Virtu Financial LLC | 111,749 | $38.0K | 0.00% | +111,749 | New |
| Citadel Advisors LLC | 55,231 | $18.0K | 0.00% | −26,703−32.6% | Reduced |
| BlackRock Inc. | 41,087 | $14.0K | 0.00% | −716−1.7% | Reduced |
| Beacon Financial Advisory LLC | 40,000 | $14.0K | 0.01% | +40,000 | New |
| Northern Trust Corp | 32,094 | $11.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 28,425 | $10.0K | 0.00% | +14,783+108.4% | Added |
| Cambridge Investment Research Advisors, Inc. | 25,250 | $9.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 25,143 | $9.00K | 0.00% | +25,143 | New |
| State Street Corp | 19,645 | $7.00K | 0.00% | +1,657+9.2% | Added |
| Commonwealth Equity Services, LLC | 20,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 12,163 | $4.00K | 0.00% | +60+0.5% | Added |
| HighTower Advisors, LLC | 13,500 | $4.00K | 0.00% | +13,500 | New |
| Alpha Cubed Investments, LLC | 10,000 | $3.00K | 0.00% | −1,000−9.1% | Reduced |
| Global Retirement Partners, LLC | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $0 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,513−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5,500−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,653−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −1,283−100.0% | Sold out |
| Capital Analysts, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −177−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |